Leap Therapeutics (NASDAQ:LPTX) jumps 7% premarket on average volume in reaction to Fast Track status in the U.S. for lead candidate DKN-01 for the treatment of DKN-01 for the treatment of patients with gastric and gastroesophageal junction (G/GEJ) adenocarcinoma whose tumors express high Dickkopf-1 protein (DKK1), following disease progression on or after prior fluoropyrimidine- and platinum- containing chemotherapy and, if appropriate, human epidermal receptor growth factor (HER2)/neu-targeted therapy.
DKN-01 is a humanized monoclonal antibody that binds to and blocks the activity of DKK1 protein, a modulator of Wnt/Beta-catenin signaling.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.